Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

503.398
0.000
Number of Gainers:4
Number of Losers:1
Number of Flat:28
PE:- -
High:503.398
Open:503.398
Low:503.398
Close:503.398
Volume:- -
Turnover:- -
Market Cap:323.35B
Float Cap:285.92B

Loading ...

InnoCare Pharma (SEHK:9969) Stock Jumps As Profit Arrives And Pipeline Risk Persists

Simply Wall St.
·
Aug 25

ZYLOXTB Allocates HK$1.18 Million for Share Buyback on August 25

Stock News
·
Aug 25

Zylox-Tonbridge Files HKEX Next-Day Disclosure After Share Repurchase Cancellation

Reuters
·
Aug 25

TH MEDICAL-B Forges Strategic Alliance with Genertec Liaoning Pharmaceutical

Stock News
·
Aug 25

ETF Market Wrap (Aug 25): Interim Results Validate Innovative Drug Sector Rally While Gold's Pullback Caps Mining Stock Gains

Stock News
·
Aug 25

午后市场反弹,A股主要指数表现分化:农业和医药板块领涨,市场成交额达1.8万亿元

Deep News
·
Aug 25

A-share Market Close | Indices Diverge While Stocks Rise Broadly; Small Appliances, Pharma, and Agriculture Lead Gains, Precious Metals Decline

Stock News
·
Aug 25

Hong Kong Stock Alert | ALEBUND-B (09637) Surges Over 6% on Dual Catalysts of Index Inclusion and Earnings, with Mircera Commercialization Poised for Growth

Stock News
·
Aug 25

Sweden's Isofol Medical Reports no Q2 Revenue, Net Loss Widens

Reuters
·
Aug 25

Everest Med Surges Over 17% in Afternoon Trade as Core Drug Nefecon Drives Strong Revenue Growth

Deep News
·
Aug 25

Midday Market Snapshot: Hang Seng Index Slips 0.25% in Morning Session, Mainland Property Stocks Rally Broadly

Stock News
·
Aug 25

Interim Results Analysis: PEIJIA-B's Core AR Product Exceeds Expectations, Reinforcing Profitability Signals and Investment Certainty

Stock News
·
Aug 25

RemeGen Swings to Profit in H1 as Revenue Surges Fivefold

MT Newswires Live
·
Aug 25

Antengene Receives Clinical Trial Approval in Australia for Phase I Attract Study of Atg-201 (Cd19 X Cd3 Tce) in B Cell-Related Autoimmune Diseases

THOMSON REUTERS
·
Aug 25

Antengene's ATG-201 Phase I ATTRACT Trial Receives Australian Ethics Committee Approval for B-Cell Autoimmune Disease Therapy

Stock News
·
Aug 25

Antengene Says Australia HREC Clears Phase 1 Attract Trial of ATG-201 in B-Cell Autoimmune Diseases

Reuters
·
Aug 25

Antengene Corp - Receives Hrec Approval for Phase I Attract Study of Atg-201 in Australia

THOMSON REUTERS
·
Aug 25

What Does The Future Hold For Ascentage Pharma Group International (HKG:6855)? These Analysts Have Been Cutting Their Estimates

Simply Wall St.
·
Aug 25

Jacobio Pharmaceuticals Appoints Xiaojie Wang as Vice Chairperson

Reuters
·
Aug 24

mRNA Sector Marks Historic Clinical Win, Everest Medicines' Self-Developed Pipeline Gains Prominence

Deep News
·
Aug 24